SEOUL & JEONJU, South Korea–(BUSINESS WIRE)– #AKC–The ASEAN-KOREA CENTRE opens Jeonju ASEAN Hall for cultural exchange, showcasing traditional heritage from 11 states.
Month: September 2026
新加坡–(BUSINESS WIRE)–(美国商业资讯)– Universal Vapor Jet Corporation (UVJC)， Universal Display Corporation (UDC) (纳斯达克股票代码: OLED) 旗下全资子公司，将于2026年10月14日至16日在中国深圳举办的湾区半导体产业生态博览会（WESEMiBAY，简称“湾芯展”）上正式发布 NovaJet。该产品是基于公司专有的 Universal Vapor Jet Printing（UVJP）技术平台所打造的首款商用系统。 此次发布标志着 UVJC 首次亮相行业展会，并在亚洲最重要的半导体展会之一的湾芯展中展示公司独特的干式、无溶剂、无掩膜薄膜沉积技术。 在 8G03 展位，NovaJet 缩比模型将作为 UVJC 展台的核心展品。同台展出的还有功能性涂层基板和印刷样品，均由位于 UVJC 新加坡总部及研发中心内的生产系统制成。 “NovaJet 是推动 UVJP 技术迈向实际生产的关键一步，”UVJC 首席执行官 Chandran Nair表示。“我们期待向参加湾芯展的客户、合作伙
SINGAPORE–(BUSINESS WIRE)—- $OLED #OLED–UVJC, a wholly owned subsidiary of UDC, today announced it will introduce NovaJet at WESEMiBAY 2026 in Shenzhen, China.
新加坡–(BUSINESS WIRE)–(美國商業資訊)– 全球顯示技術領導企業 Universal Display Corporation（UDC）（Nasdaq：OLED）旗下全資子公司 Universal Vapor Jet Corporation（UVJC） 宣布，將於 2026 年 10 月 14 日至 16 日在中國深圳舉行的 WESEMiBAY 半導體生態系大會暨展覽 上，正式發表 NovaJet。NovaJet 為首套採用其專有 Universal Vapor Jet Printing（UVJP） 技術平台打造的商用系統。 此次發表不僅是 UVJC 首次參與國際產業展覽，也將首度向亞洲最重要的半導體生態系之一展示其乾式、無溶劑且無光罩的薄膜沉積技術方案。 在 8G03 展位，UVJC 將以 NovaJet 比例模型作為展區焦點，同步展出於其新加坡總部暨研發中心已完成安裝並投入運作的生產系統所製作之鍍膜基板與列印樣品。 UVJC 執行長 Chandran Nair 表示：「NovaJet 是推動 UVJP 技術邁向實際製造應用的重要里程碑。我們期待向出席 WESEM
シンガポール–(BUSINESS WIRE)–（ビジネスワイヤ） — Universal Vapor Jet Corporation (UVJC) は, Universal Display Corporation (UDC) (Nasdaq: OLED) の100％子会社として、2026年10月14日から16日まで中国・深圳で開催される WESEMiBAY Semiconductor Ecosystem Conference and Expo において、独自の Universal Vapor Jet Printing（UVJP） プラットフォームを基盤とする初の商用システム 「NovaJet」 を発表します。 今回の発表は、UVJCにとって初の展示会出展となるものであり、アジア有数の半導体エコシステムに向けて、同社のドライ、無溶剤、マスクレスによる薄膜形成アプローチを紹介する機会となります。 ブース8G03では、NovaJetのスケールモデルを展示の中心に据えるほか、シンガポールの本社兼研究開発拠点に設置され、現在稼働中の生産システムによって製作されたコーティング基板やプリント
SINGAPORE–(BUSINESS WIRE)–Universal Vapor Jet Corporation (UVJC), een volledige dochteronderneming van Universal Display Corporation (UDC) (Nasdaq: OLED), gaat NovaJet onthullen, het eerste commerciële systeem dat is gebaseerd op haar eigen Universal Vapor Jet Printing (UVJP)-platform. Dit gebeurt tijdens de WESEMiBAY Semiconductor Ecosystem Conference and Expo in Shenzhen, China, van 14 tot en met 16 oktober 2026. Deze lancering markeert de eerste beursdeelname van UVJC en introduceert de dr
SINGAPOUR–(BUSINESS WIRE)–Universal Vapor Jet Corporation (UVJC), filiale à 100 % d’Universal Display Corporation (UDC) (Nasdaq : OLED), s’apprête à dévoiler NovaJet, le premier système commercial basé sur sa plateforme propriétaire Universal Vapor Jet Printing (UVJP), lors de la conférence et du salon WESEMiBAY Semiconductor Ecosystem qui se tiendra à Shenzhen, en Chine, du 14 au 16 octobre 2026. Ce lancement marque la première participation d’UVJC à un salon professionnel et présente l’appr
- Transformational merger reinforces Telix’s long-term growth strategy as a vertically integrated radiopharmaceutical company with enhanced capabilities across development, isotope production and global manufacturing, underpinned by commercial excellence and the industry’s most extensive therapeutic pipeline.
- ITM is the world’s leading supplier of therapeutic radioisotopes, with broad capabilities spanning lutetium-177 (177Lu), actinium-225 (225Ac) and terbium-161 (161Tb) production.
- ITM is the only producer of globally scaled commercial-grade 177Lu and serves as a key supplier for both commercially available and future therapeutic radiopharmaceuticals.
- ITM’s commercial-scale and profitable isotope production business significantly contributes to cash generation while deepening Telix’s supply chain for isotopes required for its therapeutics pipeline.
- ITM’s complementary pipeline includes ITM-11 (177Lu-edotreotide), a novel therapeutic candidate for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs), which has successfully completed Phase 3 development, potentially accelerating Telix’s entry into a validated commercial market for targeted radionuclide therapy (TRT).
- Upfront consideration of US$1.65 billion on a cash-free/debt-free basis. After adjustments, ITM Shareholders are expected to be paid approximately US$1.25 billion in Telix Shares at US$11.841 per share, released as Nasdaq ADRs after the respective escrow periods.
- Additional contingent consideration of up to US$700 million upon achievement of future regulatory approvals and commercial sales milestones for ITM-11.
- The transaction is subject to Telix Shareholder approval and other customary closing conditions.
MELBOURNE, Australia and INDIANAPOLIS and MUNICH, Sept. 21, 2026 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces it has signed a strategic agreement to lead a merger with ITM Isotope Technologies Munich SE (“ITM”), a global leader in radioisotope production and radiopharmaceutical development.
The merger will further strengthen Telix’s leadership as a vertically integrated radiopharmaceutical company with the capabilities required to develop, manufacture and deliver innovative treatments to patients globally. The combined organization will be uniquely positioned as a radiopharmaceutical industry leader, differentiated by a world-class scaled isotope manufacturing business with a validated global distribution network, a market-leading commercial precision medicine platform and the industry’s most extensive therapeutic radiopharmaceutical pipeline.
Founded in 2004, ITM is a private company with a leading commercial scale radioisotope manufacturing and global distribution network spanning over 65 countries. ITM is a key supplier of 177Lu and – with a compound annual growth rate (CAGR) of 40% from 2021 to 2025 – delivered annual revenue of US$273 million in 20252. This commercial momentum is underpinned by increasing global demand for TRT and radioisotopes for commercially approved products and assets under clinical development. The global nuclear medicine market is forecast to reach US$41 billion by 20343.
ITM’s late-stage novel pipeline is complementary to Telix and includes ITM-11 (177Lu-edotreotide), a differentiated somatostatin receptor (SSTR)-targeted treatment for GEP-NETs. ITM-11 has completed a successful Phase 3 trial (COMPETE, NCT03049189)4 and fully enrolled a second indication expansion Phase 3 study (COMPOSE, NCT04919226) with an interim analysis expected in H1 2027. If approved, ITM-11 has the potential to accelerate Telix’s entry into the commercial therapeutic market and expand its presence in neuroendocrine tumors, a commercially validated and clinically significant market for TRT.
The combined organization is expected to generate unaudited pro forma 2026 revenue and income exceeding US$1.3 billion5, based on management estimates. ITM’s radioisotope manufacturing business is profitable and generates cash flow. Continued growth from manufacturing, cost savings and further targeted synergies and pipeline optimization are expected to support a positive EBITDA6 contribution in 20277 and onward. If approved by health regulators, the launch of ITM-11 is expected to drive further upside, with the potential to generate additional high-margin therapeutic revenue in the near term.
Telix Managing Director and Group CEO, Dr. Christian Behrenbruch, said, “This merger positions Telix at the forefront of the consolidation that is occurring as the industry matures. ITM is the leader in radioisotope production, with deep scientific expertise and a track record of value-adding innovation. We have enjoyed a close working relationship with ITM for many years and there is strong management alignment for the rationale behind this transaction. By combining our complementary strengths, we will create a company with commercial scale, world-leading supply and the most exciting theranostic drug portfolio in the sector. Importantly, this combination further expands our late-stage therapeutic pipeline with two completed Phase 3 trials and deepens radioisotope security, while bringing together the mission-critical capabilities needed to deliver radiopharmaceutical treatments to patients around the world.”
ITM Chief Executive Officer, Dr. Andrew Cavey, added, “Joining two radiopharmaceutical pioneers creates a company with unmatched breadth and depth across the value chain, supported by deep expertise and talent. Our management teams have a track record of working together and a nuanced understanding of our respective commercial strengths and customer relationships. Together, we believe Telix and ITM will be uniquely positioned to capitalize on rapidly growing global demand for radiopharmaceuticals to the benefit of both shareholders and patients.”
Deal Terms
Under the terms of the agreement and subject to Shareholder approval, Telix will acquire 100% of the shares in ITM for US$1.65 billion upfront on a cash-free/debt-free basis expected as follows:
- US$1.25 billion will be paid to the sellers in the form of 105.8 million Telix shares (priced at the 30-day trailing VWAP as of signing of US$11.841) and released to the sellers as Nasdaq-listed ADRs at the end of their respective escrow periods;
- US$302 million of net debt will be assumed by Telix at closing; and
- US$96 million of management equity rollover and transaction expenses payable by the sellers8; and in each case subject to closing adjustments.
Additional contingent consideration of up to US$700 million will become payable upon the achievement of specified regulatory approvals and sales milestones for ITM-11 as set out below:
- Up to US$250 million upon U.S. Food and Drug Administration (FDA) approval of ITM-11 across three different indications:
- US$100 million upon FDA approval for expected first indication in G1-G2 GEP-NETs no later than December 31, 2027;
- US$100 million upon FDA approval for G2-G3 GEP-NETs indication no later than December 31, 2030; and
- US$50 million upon FDA approval for Lung NETs indication no later than December 31, 2031; and
- Up to US$450 million based on ITM-11 net global sales in FY 2030 in excess of US$150 million.
All milestone consideration will be payable in cash or Shares9 at Telix’s election10. Consideration paid to ITM Shareholders at closing is subject to financial adjustments at closing, indemnity holdbacks, and escrow (lockup) restrictions on the Shares issued at closing of up to 15 months which may be waived in limited part to allow the sellers to pay their tax and transaction expense liabilities.
Upon completion of the transaction, Telix Shareholders will own approximately 76.3% and ITM Shareholders will own approximately 23.7% of Telix shares on issue. The transaction has been approved by Telix’s Board of Directors and, as of signing, Shareholders holding over 90%11 of ITM’s Shares. The transaction is expected to close by the end of FY 2026 subject to Telix Shareholder approval as required under the ASX Listing Rules, regulatory approvals, and other customary closing conditions.
Refer to the Investor Presentation lodged today with the ASX for further information on the transaction.
A Notice of Meeting will be sent to Telix Shareholders for an extraordinary general meeting expected to be held in November 2026.
Advisors
Morgan Stanley Australia Limited acted as exclusive financial advisor to Telix. Sidley Austin LLP and Herbert Smith Freehills Kramer LLP acted as legal counsel to Telix. Centerview Partners acted as exclusive financial advisor to ITM. Latham & Watkins LLP acted as legal counsel to ITM.
About ITM Isotope Technologies Munich SE
ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. The company aims to meet the needs of cancer patients, clinicians, and partners through excellence in development, production, and global supply of medical radioisotopes. With improved patient benefit as the driving principle for all it does, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging two decades of pioneering radiopharma expertise, its respected industry position and its established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcomes and quality of life.
ITM is headquartered in Munich, Germany with two GMP manufacturing sites and a global distribution network spanning 65 countries. Through its agreement with Isogen, ITM has 15-year exclusive access to Bruce Power’s nuclear reactors in Canada for the irradiation services required to manufacture 177Lu. For further information, visit: www.itm-radiopharma.com
About Telix Pharmaceuticals Limited
Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease.
Telix’s commercial franchise is anchored by its precision diagnostics portfolio: Illuccix® (kit for the preparation of gallium-68 gozetotide injection), commercially available in 22 countries including the U.S., and Gozellix® (kit for the preparation of gallium-68 gozetotide injection), approved by the U.S. Food and Drug Administration (FDA) for prostate imaging, and Pixclara® (floretyrosine F 18) approved by the FDA for glioma imaging. The Company’s late-stage therapeutic pipeline includes three investigational assets in pivotal-stage trials: TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) in prostate cancer, TLX101-Tx (iodofalan 131I) in recurrent glioblastoma, and TLX250-Tx (lutetium (177Lu) girentuximab tetraxetan) in kidney cancer, additionally complemented by a deep pipeline of next generation candidates. TLX591-Tx, TLX101-Tx and TLX250-Tx have not received marketing authorizations in any jurisdiction.
Telix is headquartered in Melbourne, Australia, with operations across North America, Europe, Latin America and Asia-Pacific. For more information, visit www.telixpharma.com or follow Telix on LinkedIn, X and Facebook.
| Investor Relations | Media |
| Annie Kasparian Annie.kasparian@telixpharma.com |
Eliza Schleifstein Eliza@schleifsteinpr.com |
| Charlene Jaw Charlene.jaw@telixpharma.com |
Kathleen Noonan Kathleen.noonan@itm-radiopharma.com |
| Benedikt Orzelek Ben.orzelek@itm-radiopharma.com |
|
This announcement has been authorized for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.
Legal Notices
Cautionary Statement Regarding Forward-Looking Statements.
You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.
The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix and ITM disclaim any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.
This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Telix or ITM’s actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s and, as applicable, ITM’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix or ITM’s respective businesses and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix and ITM’s respective businesses, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of preclinical and clinical trials, and research and development programs; ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for product candidates, including the planned NDA resubmission for ITM-11 and the planned BLA resubmission for TLX250-Px, manufacturing activities and product marketing activities; sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of product candidates, if or when they have been approved; the parties’ ability to obtain an adequate supply of raw materials at reasonable costs for their respective products and product candidates; estimates of expenses, future revenues and capital requirements; the parties’ financial performance; developments relating to the parties’ respective competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on the parties’ respective businesses, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of the parties’ product candidates, if and after they have been approved. Telix or ITM’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.
Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of ITM or their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix, ITM or the respective owners. Trademark registration status may vary from country to country. Telix and ITM do not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.
©2026 Telix Pharmaceuticals Limited and ITM Isotope Technologies Munich SE. All rights reserved.
1 Based on the 30-day trailing VWAP on the ASX prior to signing of A$16.65, converted at an AUD/USD exchange rate of 0.71.
2 ITM audited financial statements (2025).
3 MEDraysintell Current Landscape of the Nuclear Medicine Market, 2025 edition.
4 Walter T, et al. The Lancet, July 2, 2026.
5 Refer to slide 20 of the Investor Presentation released by Telix to the ASX in conjunction with this announcement.
6 Earnings before interest, tax, depreciation and amortization.
7 Subject to the realization of targeted synergies and commercial timing assumptions. Excludes one-off implementation costs.
8 Sellers may allocate and sell some of the Telix Shares deducted from closing consideration to settle a portion of these transaction expenses.
9 Priced and settled at the 30-day trailing VWAP prior to milestone achievement and converted to Nasdaq ADRs.
10 Telix will seek Shareholder approval for the issue of Shares for the milestone payments based on Telix share price at signing.
11 Remaining ITM shareholders expected to sign Joinder Agreements to the Share Purchase Agreement prior to closing.
PERTH, Australia–(BUSINESS WIRE)–More than 120 artworks celebrating the enduring connection between people, Country and culture in the Pilbara will go on sale this month, as Colours of our Country returns for its 21st year. This year’s exhibition will run from 21 September to 2 October, showcasing the work of 29 Pilbara artists, including artists from the Cheeditha Art Group and Yinjaa-Barni Art Centre. A painting by Cheeditha Art Group member Wendy Warrie, titled Out on the Horizon, has been
DUBAI, United Arab Emirates, Sept. 20, 2026 (GLOBE NEWSWIRE) — FREELANDER, the British Premium Intelligent All-Terrain Brand, today announced the appointment of Al Tayer Motors and Premier Motors as its authorised distributors in the UAE, marking an important milestone in the brand’s international expansion. Lucia Mao, CEO of FREELANDER International, joined Matar Humaid Al Tayer, Vice-Chairman, Al Tayer Group, Saeed Humaid Al Tayer, Managing Director and Ashok Khanna, CEO, representing Al Tayer Motors and Premier Motors, to formalise the partnerships.
Matar Humaid Al Tayer, Vice-Chairman, Al Tayer Group, Saeed Humaid Al Tayer, Managing Director and Ashok Khanna, Chief Executive Officer, Mona Hasan Sadoun, VP – Customer Experience & Marketing, representing Al Tayer Motors and Premier Motors with Lucia Mao, Chief Executive Officer, FREELANDER International and Andrew Ding, Country Director, FREELANDER, at the signing.
As FREELANDER’s first international market, the UAE will play a strategic role in the brand’s entry into the Middle East. Preparations are underway for the upcoming Global Brand Launch, officially set for 29 September in Abu Dhabi.
Al Tayer Motors has been appointed as FREELANDER’s authorised distributor across Dubai and the Northern Emirates. The brand will also be represented by Premier Motors in Abu Dhabi. With more than 40 years of experience representing top-tier automotive brands, Al Tayer Motors and Premier Motors bring established premium-segment expertise and a comprehensive sales, service and parts network to the partnership.
“FREELANDER represents an exciting addition to our portfolio. Our deep knowledge of the local market and experience in the premium automotive sector will support the brand’s growth in the UAE,” said Saeed Humaid Al Tayer, Managing Director of Al Tayer Motors and Premier Motors. “We are committed to bringing new mobility solutions to our UAE customers.”
Together, the two distributors operate a network of 32 sales and service facilities in the UAE, with capabilities spanning vehicle logistics, parts supply, warranty management, after-sales and award-winning customer service in-store and online. As part of the launch plan, three flagship showrooms have been secured in Dubai and Abu Dhabi.
Lucia Mao, CEO of FREELANDER International, commented: “These appointments mark a significant milestone in FREELANDER’s Middle East strategy. We are confident that our partnership with these two reputable distributors will give powerful impetus to the global roll-out of FREELANDER 8.”
As the brand’s first strategic model, FREELANDER 8 is built on the brand’s three core product pillars — British Craftsmanship, Smart Confidence and All-Terrain Freedom. Representing the next chapter of Legend Reborn, it brings premium design, intelligent technologies and all-terrain capability together for Freedom Seekers. With its UAE distribution network taking shape, FREELANDER is set to host its Global Brand Launch in Abu Dhabi on 29 September, kicking off the next phase of its international expansion.
About FREELANDER
FREELANDER is a British Premium Intelligent All-Terrain brand co-created by Chery and Jaguar Land Rover. JLR leads the design and premium DNA, while Chery brings advanced technology and global top-tier supply chain capabilities. The brand is supported by a strong global foundation, including over 5,000 employees, five strategic hubs, and fully integrated capabilities spanning design, R&D, manufacturing, and global operations.
Vincent CHEN
freelander.international@mychery.com
https://www.cheryinternational.com/
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/9882e6ec-1297-49b9-a33e-15653cc035a4
https://www.globenewswire.com/NewsRoom/AttachmentNg/2af3ed44-e3de-446f-952e-8a09f9c2f739
